This study aims to identify the influence nebulised short acting β₂ agonists have on blood glucose levels when administered to patients experiencing an acute exacerbation of asthma and the resultant effect this has on health outcomes. Previous studies have suggested a direct link between the use of nebulised Salbutamol and an increase in blood glucose levels within the acute setting. This transient effect may indicate a predisposition to diabetes as well as potentially resulting in an extended recovery time from exacerbation.
The study has been developed to minimise the impact on patients and Paramedics by aligning the enrolment process with current clinical practice. It does not alter or delay the definitive care provided, and patients are not approached for research consent until they are in a suitably recovered situation. Consenting patients will be referred to their own GP for a single follow-up blood test.
For more information, please contact: Research@secamb.nhs.uk